Permethrin
As of the edition of 20 October 2026, Permethrin is a small molecule: marketed, first approved in 1986 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Nix
- First approved
- 31 March 1986 (US)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- INFECTOPHARM ARZNEIMITTEL UND CONSILIUM (ALLEMAGNE); 6 holders in all
- Withdrawn from market
- 1 January 1997 (in some regions)
- Registered trials
- 13, 1 stopped early
- Disease areas
- Infections; Skin and connective tissue
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 2 | 1 | 0 |
| Phase 3 | 8 | 7 | 0 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| GSK | Originator | 1986 to now |
| Insight Therapeutics | Applicant | 1988 to now |
| Medtech | Acquired holder | 2015 to now |
| Aurobindo Pharma | Acquired holder | 2022 to now |